Search a condition, explore drug classes, choose agents and doses. Drug interactions and disease contraindications flagged live.
Search and add conditions — drug classes for all will appear below, with cross-condition contraindications highlighted in red
Regimen
0Clinician
Select drugs from the left to build your regimen
Educational purposes only. Not a substitute for clinical judgement or pharmacist review. Always verify against current guidelines.
Patient Parameters
BSA (Mosteller formula)— m²
Academic References
Sources underpinning drug data, interactions, and paediatric dosing
Clinical Guidelines
Guideline
ESC Guidelines for Arterial Hypertension — Mancia G et al. European Heart Journal 2023; 44(28): 2670–2817
European Society of Cardiology, 2023
Guideline
ESC/HFA Guidelines for Heart Failure — McDonagh TA et al. European Heart Journal 2021; 42(36): 3599–3726. Updated supplement 2023.
European Society of Cardiology, 2021 + 2023 focused update
Guideline
ESC Guidelines for Atrial Fibrillation — Van Gelder IC et al. European Heart Journal 2024; 45(36): 3314–3414
European Society of Cardiology, 2024
Guideline
ESC Guidelines for Acute Coronary Syndromes — Byrne RA et al. European Heart Journal 2023; 44(38): 3720–3826
European Society of Cardiology, 2023
Guideline
GINA Global Strategy for Asthma Management and Prevention — Global Initiative for Asthma. ginasthma.org
GINA, 2024 update
Guideline
GOLD Global Strategy for COPD — Global Initiative for Chronic Obstructive Lung Disease. goldcopd.org
GOLD, 2024 report
Guideline
BTS/SIGN British Guideline on the Management of Asthma — British Thoracic Society / SIGN. brit-thoracic.org.uk
BTS/SIGN, 2023
Guideline
ADA Standards of Care in Diabetes — American Diabetes Association. Diabetes Care 2024; 47(Suppl 1)
ADA, 2024
Guideline
NICE Guidelines NG136 — Type 2 Diabetes in Adults — National Institute for Health and Care Excellence. nice.org.uk
NICE, 2022 update
Guideline
EULAR Recommendations for Management of Rheumatoid Arthritis — Smolen JS et al. Annals of the Rheumatic Diseases 2023; 82(1): 3–18
EULAR, 2022 update (published 2023)
Guideline
ACR Guideline for the Management of Gout — FitzGerald JD et al. Arthritis & Rheumatology 2020; 72(6): 879–895
American College of Rheumatology, 2020
Guideline
WHO Guidelines for Malaria — World Health Organization. who.int/publications/i/item/9789240086173
WHO, 2023 (updated quarterly)
Guideline
BHIVA Standards of Care for People Living with HIV — British HIV Association. bhiva.org
BHIVA, 2023
Guideline
NICE Guidelines NG187 — Vitamin D — National Institute for Health and Care Excellence. nice.org.uk
NICE, 2022
Guideline
NICE Guidelines NG216 — Epilepsies: Diagnosis and Management — National Institute for Health and Care Excellence. nice.org.uk
NICE, 2022
Guideline
NICE Guidelines CG90 — Depression in Adults — National Institute for Health and Care Excellence. nice.org.uk
NICE, 2022 update
Guideline
ISKDC Protocol — Nephrotic Syndrome in Children — International Study of Kidney Disease in Children. Kidney International 1981; 19(4): 561–573. Referenced in current IPNA guidelines 2021.
ISKDC / IPNA, 2021
Guideline
NICE NG209: Tobacco: preventing uptake, promoting quitting and treating dependence — National Institute for Health and Care Excellence
NICE, 2021 (updated 2023)
Guideline
NICE NG215: Insomnia in adults: clinical management — National Institute for Health and Care Excellence
NICE, 2022
Guideline
NICE NG23: Menopause: diagnosis and management — National Institute for Health and Care Excellence
NICE, 2015 (updated 2019)
Guideline
NICE NG193: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain — National Institute for Health and Care Excellence
NICE, 2021
Guideline
MHRA Review of HRT: risks and benefits (Hormone-replacement therapy: updated advice) — Medicines and Healthcare products Regulatory Agency
MHRA, 2020
Guideline
EAU Guidelines on Sexual and Reproductive Health (Erectile Dysfunction) — Salonia A et al. European Urology 2021; 80(3): 333–357
European Association of Urology, 2021
Guideline
NICE NG28: Type 2 diabetes in adults: management — includes guidance on GLP-1/tirzepatide for weight management
NICE, 2022 update
Drug Formularies & References
Formulary
British National Formulary (BNF) — Joint Formulary Committee. BMJ Group and Pharmaceutical Press, London. bnf.nice.org.uk
BNF 87, March 2024
Formulary
British National Formulary for Children (BNFc) — Paediatric Formulary Committee. BMJ Group and Royal Pharmaceutical Society. bnfc.nice.org.uk
Summary of Product Characteristics (SmPCs) — European Medicines Agency / MHRA. ema.europa.eu and medicines.org.uk/emc
Accessed 2023–2024
Formulary
AAP Red Book: Report of the Committee on Infectious Diseases — Kimberlin DW et al (Eds). American Academy of Pediatrics.
32nd edition, 2021–2024
Landmark Clinical Trials
Trial
EMPA-REG OUTCOME — Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. NEJM 2015; 373: 2117–2128
Trial
DAPA-HF — McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. NEJM 2019; 381: 1995–2008
Trial
EMPEROR-Reduced / EMPEROR-Preserved — Packer M et al. NEJM 2020; 383: 1413–1424 / Anker SD et al. NEJM 2021; 385: 1451–1461
Trial
PARADIGM-HF — McMurray JJV et al. Sacubitril–Valsartan vs Enalapril in Heart Failure. NEJM 2014; 371: 993–1004
Trial
ARISTOTLE — Granger CB et al. Apixaban vs Warfarin in Atrial Fibrillation. NEJM 2011; 365: 981–992
Trial
PLATO — Wallentin L et al. Ticagrelor vs Clopidogrel in ACS. NEJM 2009; 361: 1045–1057
Trial
FOURIER — Sabatine MS et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. NEJM 2017; 376: 1713–1722
Trial
LEADER — Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. NEJM 2016; 375: 311–322
Trial
SELECT — Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023; 389: 2221–2232
Trial
SUSTAIN-6 — Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NEJM 2016; 375: 1834–1844
Trial
PIONEER-6 — Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NEJM 2019; 381: 841–851
Trial
STEP 1–4 — Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021; 384: 989–1002. (STEP 1); Davies M et al. STEP 2 Lancet 2021; 397: 971–984; Wadden TA et al. STEP 3 JAMA 2021; 325: 1403–1413; Rubino D et al. STEP 4 JAMA 2021; 325: 1414–1425
Trial
REWIND — Gerstein HC et al. Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes. NEJM 2019; 381: 841–851
Trial
SCALE (Liraglutide 3mg) — Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. NEJM 2015; 373: 11–22
Trial
AWARD programme (Dulaglutide) — Multiple phase III trials (AWARD-1 through AWARD-11). Diabetes Care and Lancet Diabetes Endocrinol 2014–2021. Key: AWARD-2 Diabetes Care 2014; 37: 2149–2158; AWARD-3 Diabetes Care 2014; 37: 2168–2176
Trial
RECOVERY — RECOVERY Collaborative Group. Dexamethasone in Hospitalised Patients with COVID-19. NEJM 2021; 384: 693–704
Trial
RALES — Pitt B et al. Spironolactone in Patients with Severe Heart Failure. NEJM 1999; 341: 709–717
Trial
CIBIS-II — CIBIS-II Investigators. Bisoprolol in Heart Failure. The Lancet 1999; 353(9146): 9–13
Trial
FIDELIO-DKD / FIGARO-DKD — Bakris GL et al. / Pitt B et al. Finerenone in CKD with T2DM. NEJM 2020; 383: 2219–2229 / NEJM 2021; 385: 2252–2263
Trial
SHIFT — Swedberg K et al. Ivabradine and Outcomes in Chronic Heart Failure. The Lancet 2010; 376(9744): 875–885
Trial
REDUCE-IT — Bhatt DL et al. Cardiovascular Risk Reduction with Icosapent Ethyl. NEJM 2019; 380: 11–22
Trial
UKPDS — UK Prospective Diabetes Study Group. Intensive Blood-Glucose Control with Metformin. The Lancet 1998; 352(9131): 854–865
Trial
SANAD I & II — Marson AG et al. Standard and New Antiepileptic Drugs. The Lancet 2007; 369: 1000–1015 / SANAD II: The Lancet 2021; 397: 1363–1374
Trial
HOPE — HOPE Study Investigators. Ramipril and Cardiovascular Events. NEJM 2000; 342: 145–153
Trial
A-HeFT — Taylor AL et al. Combination of Isosorbide Dinitrate and Hydralazine in Black Patients with Heart Failure. NEJM 2004; 351: 2049–2057
Trial
EAGLES Trial — Anthenelli RM et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and NRT for smoking cessation. Lancet 2016; 387: 2507–2520
Varenicline vs NRT vs bupropion — no increased neuropsychiatric risk confirmed across all patient groups
Trial
SURMOUNT-1 — Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. NEJM 2022; 387: 205–216
20.9% mean weight reduction with tirzepatide 15mg vs 2.3% placebo at 72 weeks
Trial
SURMOUNT-5 — Head-to-head tirzepatide 10/15mg vs semaglutide 2.4mg SC for weight management. NEJM 2025
Superior weight loss with tirzepatide vs semaglutide in direct comparison
Trial
STEP-1 — Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021; 384: 989–1002
14.9% mean weight reduction with semaglutide 2.4mg SC weekly
Trial
Women's Health Initiative (WHI) — Rossouw JE et al. Risks and benefits of oestrogen plus progestin. JAMA 2002; 288: 321–333
CEE + MPA arm: VTE, breast cancer signals — informed modern HRT prescribing
Trial
E3N Cohort Study (HRT) — Fournier A et al. Unequal risks for breast cancer associated with different HRT formulations. Breast Cancer Res Treat 2008; 107: 103–111
Micronised progesterone more favourable breast cancer risk profile vs synthetic progestogens
Paediatric Dosing Sources
Paeds
BNFc (British National Formulary for Children) — Paediatric Formulary Committee. BMJ Group / RPS.
Ozempic (semaglutide SC) SmPC — Novo Nordisk. European Medicines Agency. ema.europa.eu / medicines.org.uk/emc
EMA, 2024 (last updated)
SmPC
Rybelsus (semaglutide oral) SmPC — Novo Nordisk. EMA and FDA labelling. ema.europa.eu
EMA, 2024
SmPC
Wegovy (semaglutide 2.4mg SC) SmPC / FDA Label — Novo Nordisk. US FDA and EMA. fda.gov / ema.europa.eu
FDA/EMA, 2023–2024
SmPC
Victoza (liraglutide 1.2/1.8mg) SmPC — Novo Nordisk. ema.europa.eu
EMA, 2023
SmPC
Saxenda (liraglutide 3mg) SmPC — Novo Nordisk. ema.europa.eu
EMA, 2023
SmPC
Trulicity (dulaglutide) SmPC — Eli Lilly. ema.europa.eu / medicines.org.uk/emc
EMA, 2024
Guideline
ADA/EASD Consensus Report — Management of Hyperglycaemia in T2DM — Davies MJ et al. Diabetes Care 2022; 45: 2753–2786. Incorporates CVOT data and positions GLP-1 RA / SGLT-2i in CV risk-stratified treatment algorithms.
ADA/EASD, 2022
Guideline
ESC Cardiovascular Risk Guidelines — Diabetes, Pre-diabetes and Cardiovascular Diseases — Marx N et al. European Heart Journal 2023; 44(39): 4043–4140. Recommends GLP-1 RA for CV risk reduction independent of HbA1c.
ESC, 2023
Guideline
ESAIC/GI Endoscopy Society Guidance — GLP-1 RA and Anaesthesia — Recommendations on pre-operative GLP-1 agonist withholding (gastroparesis / aspiration risk). Anaesthesia 2024; 79(4): 353–358.
ESAIC, 2023–2024
Safety
FDA Drug Safety Communication — GLP-1 RA and Thyroid C-Cell Tumours — US FDA. Boxed warning maintained in US labelling; ongoing pharmacovigilance. fda.gov/drugs/drug-safety-and-availability
FDA, continuously updated
Safety
EMA Signal Assessment — GLP-1 RA and Suicidal Ideation — European Medicines Agency. Review initiated 2023; ongoing pharmacovigilance. ema.europa.eu
EMA, 2023–2024
Safety
SUSTAIN-6 Retinopathy Sub-analysis — Vilsbøll T et al. Semaglutide and Diabetic Retinopathy Complications. Diabetes Obes Metab 2018; 20: 460–463. Rapid HbA1c reduction associated with early worsening retinopathy.
2018
This tool is for educational purposes only. Drug information is synthesised from the above sources and should always be verified against current local guidelines, SmPCs, and clinical context before application to patient care. Drug dosing and interactions may have been updated since last revision.